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In Tanzania, one of the main foci of the CGIAR Research 
Program on Livestock and Fish health flagship, both in its 
laboratory and field work, was to control East Coast fever 
(ECF) and contagious bovine pleuropneumonia (CBPP) 
affecting the smallholder dairy value chain. This brief reviews 
results from the last five years and draws lessons learned. 
East Coast fever challenges 
Scientists from the International Livestock Research 
Institute (ILRI) worked with partners to enhance access of 
smallholders to the Infection and Treatment Method (ITM) 
vaccine. The USAID-funded project, Scaling up the delivery 
of ITM in Tanzania, facilitated access to the treatment 
along the value chain by helping to establish additional 
distributors in previously unserved parts of the country. 
Additional vaccinators have also been trained and various 
ways of creating awareness among livestock keepers are 
ongoing. The project is also working with the wider 
‘Maziwa Zaidi’ project to develop other delivery models 
such as through producer organizations, dairy business 
hubs and cooperatives to link them with distributors or to 
play a role in the delivery value chain, such as providing 
cold chain.  
Demand 
Kidenke, the farmer featured in the box, is fortunate. Less 
than 5% of farmers, and animals at risk, have access to ITM 
technology. Despite its existence for the last 30 years, few 
farmers have heard of it. It has mostly been delivered 
through pilot programs. The need for specially trained 
animal health service providers to deliver the vaccine adds 
to its already high cost (vis-à-vis other vaccines). And given 
the limited market, the few distributors only cover part of 
Tanzania. This problem is not limited to Tanzania. Less 
than 2.5% of the animals at risk in countries suffering from 
ECF endemics have been vaccinated. 
Supply 
The other big issue for the ITM vaccine is its availability 
in the region. Currently the AU-supported Centre for 
Ticks and Tick-borne diseases (CTTBD) in Malawi is 
producing the vaccine, following the transfer of the 
technology by ILRI with support from GALVmed. In 
Tanzania it is estimated that about two million calves are 
born in ECF endemic areas every year. Even if only 50% 
of farmers adopt the technology, Tanzania alone would 
require at least a million doses per year. Kenya and 
Uganda could require a similar amount of doses. Can one 
production site such as the CTTBD cope with such a 
demand?  
 
Case study: ITM lifted me from poverty 
The first impression you get when you meet Nicholaus Kidenke 
is of a man at peace; content, happy, filled with hope about 
tomorrow. He smiles easily and is ready to tell his story. He first 
encountered ILRI as a beneficiary of a project to up-scale  
delivery of the East Coast fever (ECF) vaccine, commonly known 
as the ‘Infection and Treatment Method’ (ITM). The name comes 
from the fact that the vaccine infects healthy cattle with specific 
strains of the causative agent, Theileria parva and simultaneously 
injects them with a long acting antibiotic. This results in a mild 
reaction leading to immunity for life. 
 
Kidenke, now a wealthy farmer, attributes his fortune to the 
effectiveness of ITM. Kidenke had about 800 cattle but started to 
lose calves, 75% in one year. A veterinarian diagnosed East Coast 
fever, and advised him to increase the frequency of tick control. 
But nothing worked. The same veterinarian told him about a 
recently launched vaccine (ITM). But the nearest supplier was 
1800 km away. Kidenke was willing, but the control costing USD 
8 per animal was prohibitive. 
 
He sold several bulls and convinced the vaccine supplier to come 
to Ngara for the cost of the journey and lodgings. Of the 100 
animals vaccinated, he only lost 20. The following year, he lost 5, 
a huge improvement. He had found a solution. But the cost was 
still prohibitive. He informed his neighbours and together they 
were able to get their animals vaccinated for the cost of the drug. 
The group has now become an organization representing the 
interests of livestock keepers and Kidenke is the secretary. 
 
He has since bought a new farm and has close to 2000 cattle. 
When the vaccine is available, he gets all his calves vaccinated 
each year. Kidenke now wishes to invest in improving his animals 
as he no longer fears ECF. Delighted the ITM project has helped 
establish a vaccine distributor in Kahama, some 300km from 
Ngara, the cost of the vaccine is still problematic, and it is difficult 
to deliver as it requires specially trained personnel who are in 
short supply in Tanzania 
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Dosage 
The commercial scale batches of the ECF-ITM vaccine 
produced by ILRI and CTTBD were supplied in straws 
containing 32 and 40 doses each, respectively. Each straw 
must be thawed and diluted immediately prior to use. Once 
thawed, the vaccine must be used within four hours and any 
vaccine unused by that time must be discarded. Whilst this is 
not a major problem when vaccinating large herds in 
pastoralist settings, use of the vaccine in smallholder settings, 
where each smallholder may have two or three cattle, can 
lead to substantial wastage of the vaccine. 
Transmission from buffalo 
The natural reservoir of Theileria parva is the African 
buffalo. Although the vaccine has proven very effective in 
cattle infected, via the tick vector, from other cattle, there 
is conflicting evidence in the scientific literature concerning 
the ability of vaccinated cattle to withstand challenge from 
ticks which have fed on buffalo. Prompted by reports of 
clinical ECF cases in vaccinated cattle on a conservancy 
where cattle co-graze with buffalo, ILRI scientists 
undertook a controlled field trial which showed that the 
vaccine had little effect in protecting cattle against buffalo-
derived parasites (Sitt et al. 2015). 
Underreporting 
Reproductive diseases especially in smallholder dairy systems 
have probably been underreported. These reproductive 
diseases could be partly responsible for the long calving 
intervals reported in smallholder dairy systems together with 
poor nutrition and poor heat recognition by smallholder dairy 
keepers. Recently ILRI under the Agricultural Technology 
Transfer project has started to investigate the importance of 
reproductive diseases in smallholder dairy systems in Tanzania. 
The information collected will inform further research into this 
neglected area. One major constraint has been the lack of easy 
diagnostic tools for some of the diseases; this area of research 
could contribute to addressing the issue, especially the need for 
effective point-of-care tests used by farmers. 
ECF achievements 
Deploying the vaccine 
In 2007/8, ILRI produced the second commercial-scale 
batch of the ECF-ITM Muguga cocktail vaccine. In rececent 
years, supply of the vaccine to approved distributors 
became an activity of the flagship. Since 2012, 594,600 
doses of the vaccine were distributed, predominantly to 
Tanzania (85%), Uganda (7%) and Kenya (6%). There were 
no substantiated reports of vaccine failure from any of the 
distributors or livestock owners, apart from cattle co-
grazing with buffalo (see above). It has been estimated that 
594,600 doses of the vaccine protected at least 220,000 
cattle from ECF-related deaths, assuming a fatality rate of 
40% and 10% in a susceptible herd of pastoral and dairy 
cattle respectively, in addition to making savings on 
reduced acaricide use and cost of treatment. 
Fewer-dose straws 
To overcome the dosage constraint, ILRI demonstrated 
that the vaccine straws can be thawed, diluted, repackaged 
and refrozen with minimal loss of viability. An initial, 
experimental production resulted in straws containing 5–8 
doses (Patel et al. 2016). With VetAgro Ltd from Tanzania, 
ILRI showed that the vaccine was safe and effective under 
both experimental and field conditions. 
Characterizing the vaccine 
The Muguga cocktail, the most widely used version of the 
ECF-ITM live vaccine is a mix of three parasite isolates. 
Obtaining clear knowledge of the composition of the 
vaccine is important for: quality control of successive 
batches; studying transmission in field situations; and 
acquiring a better understanding of its mechanism of 
action. Scientists in the Flagship contributed to this in two 
ways. First, using mini- and micro satellite markers they 
confirmed the existence of 14 different strains (genotypes) 
of the parasite in the vaccine stabilate (Patel et al. 2011). 
Second, flagship scientists demonstrated the amount of 
antigenic variation among the vaccine parasites was 
relatively limited (Hemmink et al. 2016). The latter 
observation is important as it was originally thought that 
the broad protection provided by the multi-isolate Muguga 
cocktail, compared to single isolates, was due to a greater 
degree of antigenic variation. This means that possibly a 
simpler cocktail could also be sufficient to convey 
protection, and thus make production easier. 
Improved manufacturing process 
In 2016, a study of the full production process for the 
Muguga cocktail ECF-ITM by flagship scientists recorded 
several improvements to the process introduced in the 
1996 and 2008 commercial-scale batches produced by ILRI 
(Patel et al. 2016). This will serve as an important 
reference document for future production. In addition, the 
article documented the production and characteristics of 
the ‘reference’ stabilates made in 2008. These stabilates 
are intended to be the ‘seed’ stabilates from which future 
batches of the vaccine will be made. 
Stakeholder engagement 
With GALVmed, the health flagship convened a workshop 
in August 2014 of interested parties to discuss the status 
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and challenges associated with ECF-ITM vaccine. The 
participants—a range of actors involved in the manufacture 
and deployment of the vaccine in the affected countries--
identified a list of priority items needed to improve the 
manufacture, distribution and use of the live vaccine (Toye 
and Ballantyne 2015). 
Tolerance to Theileria parva infection 
A surprising observation from the field trial described 
above is that the progeny of a particular ILRI sire appeared 
to be tolerant to buffalo-derived T. parva infection. This 
observation has now been confirmed in subsequent field 
trials using further progeny of this sire (Toye et al. 
unpublished data). In a collaboration with the Roslin 
Institute, flagship scientists are seeking to identify the 
genetic region responsible for this tolerance. The findings 
should lead to a genetic marker for breeding tolerant 
cattle, while identification of the mechanism mediating the 
tolerance may help the identification of new vaccine or 
therapeutic targets. 
Developing a next-generation vaccine 
In addition to the need for a liquid nitrogen cold chain to 
deliver the ITM, the vaccine’s cost and the complexity of 
producing it, the use of live parasites for vaccination 
increases the risk of spreading the parasite to non-immune 
animals from vaccinated animals.  
 
Flagship scientists are thus working on 2 strategies to 
discover a cheaper and safer sub-unit vaccine: 
 
The first is to gain a greater understanding of the 
immune mechanisations elicited during the ITM 
vaccination, since ITM induces a strong cytotoxic T 
lymphocyte (CTL) response and, part of the immunity 
conferred needed in a subunit vaccine. 
 
As a first step, laboratory reagents needed to be 
developed to enable the assessment of the antigen-specific 
CTL immune response in cattle immunized with T. parva, 
or with recombinant CTL antigens of the parasite. These 
reagents are recombinant major histocompatibility (MHC) 
class I molecules, known as bovine leukocyte antigen 
(BoLA) class I molecules in cattle. A library of 15 different 
BoLA molecules, covering the major BoLA molecules 
present in Holstein/Friesian cattle of Kenya were 
expressed, purified, and, since eight CTL lines expressing 
the correct BoLa class I type were available, eight of them 
were tested in vitro with this bank of CTL lines from T. 
parva immune animals. These reagents have allowed us to 
characterize more specifically, by flow cytometry, the 
phenotype of CTL elicited towards the known 
immunodominant T. parva antigen Tp1. Moreover, the use 
of these BoLA molecules, in conjunction with the use of an 
immunoinformatics (reverse immunology) platform, 
allowed us to identify the exact minimal CTL epitope of a 
known T. parva antigen (Tp2) as well as a new BoLA 
specificity of a known CTL epitope. 
 
The second is to identify antigens that could be 
included in a subunit vaccine. It is already known that 
ITM-immunized animals develop CTL that kill parasite-
infected cells, and that some antigens of the parasite 
induce that response; Tp1 antigen being one and p67 
another (the latter being the major surface protein on the 
parasite at the sporozoite stage). 
Flagship scientists tested several methods to deliver the Tp1 
antigen, the p67 antigen or both antigen together in groups of 
13 to 15 cattle, to see if the target of 70% level of protection 
could be reached. Upon infecting the three immunized groups 
of cattle with an LD100 infecting dose of the parasite, 33% 
were shown to be immune in the p67C only group, 27% 
were immune in the Tp1 only group, and 46% of the animals 
in the combined p67C & Tp1 antigens group were immune. 
Though the 70% target level of protection has not been 
achieved, it is clear that combining antigens can increase 
immunity levels. Repeat experiments are planned using an 
LD70 infecting dose which is more representative of what is 
happening in the field. 
Contagious bovine pleuropneumonia 
CBPP, another major cattle disease, is caused by 
Mycoplasma mycoides subsp. mycoides (Mmm). The existing 
vaccine, a live attenuated vaccine, confers limited 
protection and causes a reaction discouraging farmers 
from presenting animals for vaccination. But perhaps the 
biggest constraint to delivery is its short duration of 
protection; it requires re-vaccination within a year. The 
available diagnostics are good at herd level, not at an 
individual cow level, thus limiting the control of the 
disease. 
 
Flagship scientists have taken two approaches to the 
development of an improved vaccine: 
 
The first is to study host-pathogen interactions, 
specifically trying to understand the immunological 
responses to broaden the basic knowledge of the disease, 
and identify immune targets for subunit vaccines. In efforts 
to understand the underlying immunological mechanisms 
of CBPP, scientists have characterized the core surface 
proteome (Krasteva et al. 2014). They also examined 
antigen specific antibody responses towards 65 surface 
proteins for up to 232 days post infection, and observed 
that high antibody titres did not protect against formation 
of Mycoplasma containing sequestra in the lungs of 
infected cattle (Schieck et al. 2014). 
 
The second is to employ state-of-the-art synthetic 
genomics tools to engineer Mycoplasma mycoides subsp. 
capri to explore the function of specific genes/molecular 
structures of the bacteria. 
 
Synthetic biology tools have been established at ILRI, such 
as genome transplantation for Mycoplasma mycoides subsp. 
capri (Mmc) which infects goats and is the closest relative 
of Mmm, the causative agent of CBPP. Flagship scientists 
generated a mutant strain which lacks the terminal gene in 
the galactofuranose synthesis pathway. This mutant lacks 
galactofuranose polysaccharide coating the surface of the 
bacteria. In vitro, this mutant showed increased cell 
membrane permeability, enhanced adhesion to host cells 
and increased resistance to serum killing activity compared 
to the wild type (Schieck et al. 2016). Preliminary data 
show that the galactofuranose polysaccharide is a virulence 
factor and the mutant is a promising vaccine strain for 
Mmc and this knowledge will inform the vaccine 
development for CBPP. 
 
Computational modelling has shown that improved 
diagnostic tools will also be crucial to eliminate CBPP 
(Ssematimba et al. 2015). 
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Lessons learned 
 Production of ITM has several uncertainties it would 
be less risky if there were more than one producer of 
the vaccine. Given the disease spreads from South 
Sudan to Mozambique and given the logistically 
complexities of transportation, it would also seem 
that having the production in more than one 
geographic region would help. 
 It is important that ILRI continue to engage long after 
products have been developed and transferred to 
producers. The question is perhaps how long this 
should continue. It is clear that some of the impacts 
may not have been realised unless ILRI continues to 
engage with the relevant partners to ensure the 
product goes to scale. 
 In hindsight perhaps, ILRI should have spent more 
research effort in improving the ITM technology. For 
instance more effort should have been put into 
research to produce a smaller dose package. This 
would probably enhance adoption of the technology 
among smallholders. 
 To form hypotheses and theories and test them, more 
basic knowledge on mycoplasma and the interaction of 
different species with their hosts (e.g. ruminants) is 
needed. Existing infection models are also sub-optimal 
and need to be improved. More samples are needed 
from the field and more opportunities need to be 
created for discussion with epidemiologists about 
prevalence and transmission to inform lab work. 
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